A method according to claim 6, characterized by using an antagonist to CGRP fragment 30-37 or 32-37. Only pharmaceutically active and physiologically acceptable antagonists to above mentioned peptide fragments are of course intended to be used according to this invention.ħ.

The present invention thus relates to antagonists of CGRP and active fragments thereof, particularly fragments 32-37 and 30-37 and derivatives and analogues of such fragments, for preventing miosis as is liable to occur as a consequence of intraocular surgery, trauma, or uveitis and iritis. Blockage here can be effected by way of local and/or optionally general administration of the antagonist. The possibility of preventing undesired noncholinergic miosis by means of antagonists to fragments of CGRP, particularly fragment 32-37 is now presenting itself as a highly interesting, novel concept for potential therapies of practical importance, in the first place in such contexts where the lens is being extracted and this is then followed by insertion of an artificial lens, but also in contexts of other intraocular surgeries, for instance surgery in the posterior segment. When synthetically produced substance P was injected into the anterior chamber this produced a substantialĬontractive-response of the sphincter muscle of the iris, thus suggesting that this miosis is brought about by the said peptide or a closely related substance. Miosis caused by irritation has been studied thoroughly in experimental animals and it has been found for instance that in rabbits - such irritation is caused by a peptide very similar to or identical with substance P released in the eye (Bill et al., 1979). In cases of uveites (inflammation of the uvea), especially iritis, this type of miosis will sometimes give rise to very undesirable synechiae between the. Clinically miosis of the type produced by irritation often implies substantial complications, e.g. Such miosis cannot be prevented by antagonists of acetylcholine such as e.g. In particular this occurs as part of the eye's response to various kinds of irritation. miosis, can be caused by mechanisms other than acetylcholine release. It has been known for a long time that constriction of. A61K38/225- Calcitonin gene related peptide.A61K38/17- Peptides having more than 20 amino acids Gastrins Somatostatins Melanotropins Derivatives thereof from animals from humans.A61K38/16- Peptides having more than 20 amino acids Gastrins Somatostatins Melanotropins Derivatives thereof.A61K38/00- Medicinal preparations containing peptides.A61K- PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES.

A61- MEDICAL OR VETERINARY SCIENCE HYGIENE.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from SE9201425-7 external-priority Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab Publication of WO1993021911A1 publication Critical patent/WO1993021911A1/en Links Inventor Birgitta ALMEGÅRD Anders Bill Johan Stjernschantz Original Assignee Kabi Pharmacia Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google Patents WO1993021911A1 - Method and means for preventing constriction of the pupil in the eye WO1993021911A1 - Method and means for preventing constriction of the pupil in the eye

Timolol pupil constriction